Oral microbiota and liver diseases

Bibliographic Information
Authors: Elghannam M.T.; Hassanien M.H.; Ameen Y.A.; Turky E.A.; Elattar G.M.; ElRay A.A.; Eltalkawy M.D.
Journal: Clinical Nutrition ESPEN
Publisher: Elsevier Ltd
Publication Date: April 2023
Volume / Issue: Volume 54
Pages: 68–72
ISSN: 24054577
DOI: 10.1016/j.clnesp.2022.12.030
Scopus: View on Scopus
PubMed: 36963900
Document Type: Review
Authors and Affiliations
Elghannam M.T., TBRI, Warak ALHadar, P.O. Box 30 Imbaba, Cairo, Egypt, Hepatogastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt; Hassanien M.H., Hepatogastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt; Ameen Y.A., Hepatogastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt; Turky E.A., Hepatogastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt; Elattar G.M., Hepatogastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt; ElRay A.A., Hepatogastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt; Eltalkawy M.D., Hepatogastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt
Abstract
Gut microbiota plays a crucial role in our health and particularly liver diseases, including NAFLD, cirrhosis, and HCC. Oral microbiome and its role in health and disease represent an active field of research. Several lines of evidence have suggested that oral microbiota dysbiosis represents a major factor contributing to the occurrence and progression of many liver diseases. The human microbiome is valuable to the diagnosis of cancer and provides a novel strategy for targeted therapy of HCC. The most studied liver disease in relation to oral–gut–liver axis dysbiosis includes MAFLD; however, other diseases include Precancerous liver disease as viral liver diseases, liver cirrhosis, AIH and liver carcinoma (HCC). It seems that restoring populations of beneficial organisms and correcting dysbiosis appears to improve outcomes in liver disorders. We discuss the possible role of oral microbiota in these diseases. © 2023 European Society for Clinical Nutrition and Metabolism
Keywords
AIH; HCC; Oral microbiota; Oral-gut-liver axis dysbiosis; Viral liver diseases; Carcinoma, Hepatocellular; Dysbiosis; Humans; Liver Cirrhosis; Liver Neoplasms; Microbiota; gamma interferon; granulocyte colony stimulating factor; interleukin 12p70; interleukin 17; interleukin 1beta; interleukin 4; interleukin 6; interleukin 7; interleukin 8; lipopolysaccharide; probiotic agent; tumor necrosis factor; autoimmune hepatitis; bacterial colonization; chronic viral hepatitis; disease exacerbation; fecal microbiota transplantation; human; intestine flora; liver cell carcinoma; liver disease; metabolic syndrome X; mouth flora; nonalcoholic fatty liver; oral gut liver axis dysbiosis; precancer; Prevotella; Review; Veillonella; liver tumor; microflora
Citation Information
Scopus Citations: 19
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
